File: '\\swfile\EmailIn\20240418 115854 Attachment 240418 BHSC NR Note Conversion Final.docx'

CSE:BHSC - FSE:8MV - OTC: CNVCF OFSE:8MV

NR: 041824-1

BioHarvest Sciences Announces Conversion of Debt Notes

Vancouver, British Columbia and Rehovot, Israel - April 18, 2024 - BioHarvest Sciences Inc. ("BioHarvest" or the "Company") (CSE: BHSC) (OTCQB: CNVCF), a biotechnology company pioneering its patented Botanical Synthesis technology platform, today announced an early conversion of convertible debt notes, associated with the convertible debt financing rounds completed on October, November 2022 and July, October, December 2023.

BioHarvest reports that a total of CAD $5,675,059.91 (principal loans plus accrued interest) has been converted into 22,826,132 common shares. As part of the term of October and December 2023 convertible loans, the Company issued 3,090,284 "Early Exercise" warrants at USD 0.222 for early conversion. 2,917,987 "Early Exercise" warrants will expire on October 30, 2025, and 172,297 will expire on December 22, 2025.

Terms of the Convertible Notes:

For the terms of the convertible notes, please refer to the following press releases:

October & November 2022

https://webfiles.thecse.com/221007-NR.pdf?4WMbE8ensjbbbEsu0wojG_aIToytzq8u

July 2023

https://webfiles.thecse.com/070723_BHSC_NR_Announces_Financing.pdf?shRURERy5GmbMlENr6Fx4hBNoZrxV9GI

October & December 2023

https://webfiles.thecse.com/192422.pdf?c5rmqUZwELcsf0SPeBlyFWtCt3xUl00q

About BioHarvest Sciences Inc.

BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) (FSE: 8MV) is a leader in Botanical Synthesis, leveraging its patented technology platform to grow plant-based molecules, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and production organization (CDMO) on behalf of customers seeking complex molecules, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. To learn more, please visit www.bioharvest.com.

Forward-Looking Statements

Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.

Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.

This release has been reviewed and approved by Dave Ryan, VP Investor Relations, who accepts responsibilities for its contents.

BioHarvest Corporate Contact:

Dave Ryan, VP Investor Relations & Director

+1 (604) 622-1186

info@bioharvest.com

Investor Relations Contact:

Lucas A. Zimmerman

Managing Director

MZ Group - MZ North America

+1 (949) 259-4987

BHSC@mzgroup.us